Supernus Pharmaceuticals (SUPN) Earnings Date, Estimates & Call Transcripts $33.20 +0.15 (+0.45%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Supernus Pharmaceuticals Earnings Summary Supernus Pharmaceuticals announced Q3 2024 earnings on November 4, 2024, reporting an EPS of $0.69, which beat the consensus estimate of $0.44 by $0.25. Quarterly revenue rose 14.2% year-over-year to $175.70 million, above analyst estimates of $157.35 million. With a trailing EPS of $1.11 and a P/E Ratio of 31.03, Supernus Pharmaceuticals' earnings are expected to decrease -39.50% next year, from $2.38 to $1.44 per share. Upcoming Q4 Earnings DateAug. 5After Market ClosesEstimatedConsensus EPS (Nov. 4) $0.44 Actual EPS (Nov. 4) $0.69 Beat By $0.25 Actual Revenue (Nov. 4) $175.70MQ3 2024 Earnings ResourcesQ3 2024 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)SEC FilingSUPN Upcoming EarningsSupernus Pharmaceuticals' next earnings date is estimated for Tuesday, August 5, 2025, based on past reporting schedules. Powered by Get Supernus Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Supernus Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSUPN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SUPN Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Supernus Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $2.38 EPSNext Year EPS Consensus Estimate $1.44 EPS Supernus Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/5/2025(Estimated)--------11/4/2024Q3 2024$0.44$0.69+$0.25$1.21$157.35M$175.70M8/6/2024Q2 2024$0.39$0.36 -$0.03$0.36$148.83M$168.30M2/27/2024Q4 2023$0.41$0.02 -$0.39$0.02$155.03M$164.30M11/8/2023Q3 2023$0.13-$0.29 -$0.42-$0.29$143.39M$153.88M8/8/2023Q2 2023$0.23-$0.02 -$0.25-$0.02$143.63M$135.56M Supernus Pharmaceuticals Earnings - Frequently Asked Questions When is Supernus Pharmaceuticals's earnings date? Supernus Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 5th, 2025 based off last year's report dates. Learn more on SUPN's earnings history. What guidance has Supernus Pharmaceuticals issued on next quarter's earnings? Supernus Pharmaceuticals updated its FY 2025 earnings guidance on Tuesday, May, 6th. The company issued revenue guidance of $600.0 million-$630.0 million, compared to the consensus revenue estimate of $624.7 million. Did Supernus Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Supernus Pharmaceuticals (NASDAQ:SUPN) reported $0.69 earnings per share (EPS) to beat the analysts' consensus estimate of $0.44 by $0.25. Learn more on analysts' earnings estimate vs. SUPN's actual earnings. How can I listen to Supernus Pharmaceuticals's earnings conference call? The conference call for Supernus Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Supernus Pharmaceuticals's conference call transcript? The conference call transcript for Supernus Pharmaceuticals's latest earnings report can be read online. Read Transcript How can I view Supernus Pharmaceuticals's earnings report? Supernus Pharmaceuticals's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Supernus Pharmaceuticals generate each year? Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded annual revenue of $668.00 million. How much profit does Supernus Pharmaceuticals generate each year? Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded net income of $1.32 million. SUPN has generated $1.11 earnings per share over the last four quarters. What is Supernus Pharmaceuticals's price-to-earnings ratio? Supernus Pharmaceuticals (NASDAQ:SUPN) has a trailing price-to-earnings ratio of 31.03 and a forward price-to-earnings ratio of 13.95. What is Supernus Pharmaceuticals's EPS forecast for next year? Supernus Pharmaceuticals's earnings are expected to decrease from $2.38 per share to $1.44 per share in the next year, which is a -39.50% change. More Earnings Resources from MarketBeat Related Companies JAZZ Earnings Results PRGO Earnings Results PCRX Earnings Results OMER Earnings Results NKTR Earnings Results ASMB Earnings Results CPIX Earnings Results LLY Earnings Results JNJ Earnings Results ABBV Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds This page (NASDAQ:SUPN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
